Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group

C. B. Pratt, B. A. Kamen, N. Winick, P. Sartain, J. E. Champion, A. H. Ragab, M. P. Goren

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m2 iv over 2 hours every 3-4 weeks.

Original languageEnglish (US)
Pages (from-to)87-88
Number of pages2
JournalCancer Treatment Reports
Volume71
Issue number1
StatePublished - Mar 25 1987

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group'. Together they form a unique fingerprint.

  • Cite this

    Pratt, C. B., Kamen, B. A., Winick, N., Sartain, P., Champion, J. E., Ragab, A. H., & Goren, M. P. (1987). Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group. Cancer Treatment Reports, 71(1), 87-88.